Krishna Institute Of Medical Sciences Ltd vs Nephrocare Health Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 04, 2026

Key Highlights

The Latest Trading Price of Krishna Institute of Medical Sciences Ltd is ₹ 626.15 as of 02 Apr 15:30 . The P/E Ratio of Krishna Institute of Medical Sciences Ltd changed from 33.2 on March 2022 to 66.5 on March 2025 . This represents a CAGR of 18.97% over 4 yearsThe P/E Ratio of Nephrocare Health Services Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Krishna Institute of Medical Sciences Ltd changed from ₹ 11043 crore on March 2022 to ₹ 25580 crore on March 2025 . This represents a CAGR of 23.37% over 4 yearsThe Market Cap of Nephrocare Health Services Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Krishna Institute of Medical Sciences Ltd for the Dec '25 is ₹ 1002 crore as compare to the Sep '25 revenue of ₹ 964.9 crore. This represent the growth of 3.94% The revenue of Nephrocare Health Services Ltd for the Dec '25 is ₹ 263.05 crore as compare to the Sep '25 revenue of ₹ 249.61 crore. This represent the growth of 5.38% The ebitda of Krishna Institute of Medical Sciences Ltd for the Dec '25 is ₹ 204.1 crore as compare to the Sep '25 ebitda of ₹ 207.9 crore. This represent the decline of -1.83% The ebitda of Nephrocare Health Services Ltd for the Dec '25 is ₹ 64.18 crore as compare to the Sep '25 ebitda of ₹ 67.82 crore. This represent the decline of -5.37% The net profit of Krishna Institute of Medical Sciences Ltd changed from ₹ 95.2 crore to ₹ 51.9 crore over 7 quarters. This represents a CAGR of -29.30% The net profit of Nephrocare Health Services Ltd changed from ₹ 20.11 crore to ₹ 32.24 crore over 5 quarters. This represents a CAGR of 45.88% The Dividend Payout of Krishna Institute of Medical Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Nephrocare Health Services Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Limited (KIMS) was erstwhile incorporated as Jagjit Singh and Sons Private Limited', a Private Limited Company on July 26, 1973 in Mumbai.
Subsequently, the name of the Company changed to Krishna Institute of Medical Sciences Private Limited' on January 2, 2004 and further upon its conversion to a Public Company, the name was changed to Krishna Institute of Medical Sciences Limited' on January 29, 2004. The Company is one of the largest corporate groups in India, with hospitals in Telangana, Andhra Pradesh & Maharashtra providing multi-disciplinary integrated services with a focus on tertiary and quaternary healthcare at affordable cost.
It is engaged in rendering medical and healthcare services.
It operate 12 multi-specialty hospitals under the 'KIMS Hospitals' brand, with an aggregate capacity of over 5000 beds.

About Nephrocare Health Services Ltd

Nephrocare Health Services Limited was incorporated as 'Nephrocare Health Services Private Limited', a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009.
Company was converted into a public limited company and the name was changed to 'Nephrocare Health Services Limited' with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy.
The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad.
It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd.

FAQs for the comparison of Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd

Which company has a larger market capitalization, Krishna Institute of Medical Sciences Ltd or Nephrocare Health Services Ltd?

Market cap of Krishna Institute of Medical Sciences Ltd is 25,054 Cr while Market cap of Nephrocare Health Services Ltd is 5,289 Cr

What are the key factors driving the stock performance of Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd?

The stock performance of Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd?

As of April 4, 2026, the Krishna Institute of Medical Sciences Ltd stock price is INR ₹626.15. On the other hand, Nephrocare Health Services Ltd stock price is INR ₹527.2.

How do dividend payouts of Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd compare?

To compare the dividend payouts of Krishna Institute of Medical Sciences Ltd and Nephrocare Health Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.